A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

PHASE3CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

May 25, 2018

Primary Completion Date

April 13, 2021

Study Completion Date

April 13, 2021

Conditions
Depressive Disorder, Treatment-Resistant
Interventions
DRUG

Esketamine 56 mg

Participants will self-administer 56 mg of esketamine as intranasal spray.

DRUG

Esketamine 84 mg

Participants will self-administer 84 mg of esketamine as intranasal spray.

DRUG

Placebo

Participants will self-administer matching placebo as intranasal spray.

DRUG

Duloxetine (Oral Antidepressant)

Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).

DRUG

Escitalopram (Oral Antidepressant)

Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.

DRUG

Sertraline (Oral Antidepressant)

Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.

DRUG

Venlafaxine Extended Release (XR) (Oral Antidepressant)

Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.

Trial Locations (30)

10128

The Medical Research Network, LLC, New York

20877

CBH Health, Gaithersburg

30331

Atlanta Center for Medical Research, Atlanta

73106

IPS Research Company, Oklahoma City

100088

Beijing Anding Hospital of Capital Medical University, Beijing

100096

Beijing HuiLong Guan Hospital, Beijing

100191

Peking University Sixth Hospital, Beijing

210000

Nanjing Brain Hospital Affilicated to Nanjing Medical University, Nanjing

300222

Tianjin Anding Hospital, Tianjin

310000

Hangzhou Seventh People's Hospital, Hangzhou

310003

First Hospital, Zhejiang University Medical College, Hangzhou

310009

The Second Affiliated Hospital of Zhejiang University, Hangzhou

313000

Huzhou third people's Hospital, Huzhou

361012

Xiamen Xianyue Hospital, Xiamen

401147

Chongqing Mental Health Center, Chongqing

410007

The Second People's Hospital of Hunan Province / Brian Hospital of Hunan Province, Changsha

410011

The second Xiangya Hospital of Central South University, Changsha

430060

Renmin Hospital of Wuhan University, Wuhan

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510000

the 3rd Affiliated Hospital,Sun Yansen University, Guangzhou

510100

Guangdong Provincial People's Hospital, Guangzhou

610041

West China Hospital Sichuan University, Chengdu

650032

First Affiliated Hospital of Kunming Medical Unversity, Kunming

710061

The First Affiliated Hospital of Xian Jiaotong University, Xi'an

Xi'an Mental Health Center, Xi'an

830000

Urumqi fourth Hospital, Ürümqi

830054

The first affiliated hospital of Xinjiang medical university, Ürümqi

71104-2136

Biomedical Research Foundation of Northwest Louisiana, Shreveport

02472

Adams Clinical, Watertown

050031

The First Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03434041 - A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | Biotech Hunter | Biotech Hunter